Fingolimod

• Description :

  Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].

• Product Name Alternative :

  FTY720 free base

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  LPL Receptor; PAK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/fingolimod.html

• Purity :

  99.97

• Solubility :

  DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 7.69 mg/mL (ultrasonic)

• Smiles :

  OCC(CCC1=CC=C(CCCCCCCC)C=C1)(N)CO

• Molecular Formula :

  C19H33NO2

• Molecular Weight :

  307.47

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Rolin J, et al. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immunother. 2010, 59 (4), 575-586.|[2]Szepanowski F, et al. Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. J Neuroinflammation. 2016 Jun 10;13 (1) :143.|[3]Airas L, et al. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis. J Nucl Med. 2015 Feb;56 (2) :305-10.|[4]Shirakabe K, et al. Modification of lymphocyte migration to Peyer's patches by inhibition of sphingosine-1-phosphate lyase ameliorates murine colitis. J Gastroenterol Hepatol. 2018 Jan 15.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  PAK1

• Citation 01 :

  Am J Physiol Cell Physiol. 2023 Nov 1;325 (5) :C1354-C1368.|Biomed Chromatogr. 2024 Jun 26:e5947.|Commun Biol. 2021 Mar 25;4 (1) :399.|Front Endocrinol. 2018 Mar 22:9:120.|Front Pharmacol. 2018 Oct 31:9:1237.|Helicobacter. 2019 Oct;24 (5) :e12652.|Hum Reprod Open. 2025 May 14;2025 (3) :hoaf027.|Immunity. 2024 Feb 13;57 (2) :364-378.e9.|J Gastroenterol Hepatol. 2018 Jan 15.|J Integr Neurosci. 2024 Aug 12;23 (8) :142.|J Med Chem. 2025 Oct 17.|J Mol Cell Cardiol. 2022 Mar:164:110-125.|Mol Neurobiol. 2024 Apr;61 (4) :1936-1952.|Res Sq. 2024 Oct 18.|Research (Wash D C) . 2025 Apr 15:8:0662.|Research Square Preprint. 2023 Sep 6.|Research Square Preprint. 2024 Apr 23.|RSC Adv. 2024 Jul 12;14 (30) :22044-22055.|Wound Repair Regen. 2023 Jul-Aug;31 (4) :489-499.|Adv Sci (Weinh) . 2024 Jul 23:e2404080.|Adv Sci (Weinh) . 2025 Aug 30:e07330.|Autophagy. 2024 Nov;20 (11) :2490-2510.|Bioorg Chem. 2024 Jun:147:107412.|BMC Microbiol. 2025 May 16;25 (1) :299.|Breast Cancer Res. 2017 Aug 4;19 (1) :90. |Cancer Cell. 2025 Feb 10;43 (2) :213-231.e9.|Cancer Immunol Immunother. 2025 Mar 25;74 (5) :161.|Cancer Immunol Immunother. 2025 Oct 6;74 (11) :326.|Cancer Lett. 2018 Nov 1:436:75-86.|Cardiovasc Res. 2025 Nov 11:cvaf215.|Cell Death Dis. 2025 Jan 20;16 (1) :31.|Cell Metab. 2025 Oct 24:S1550-4131 (25) 00395-X.|Cell Rep Med. 2024 Jun 18;5 (6) :101590.|Cell Res. 2022 May;32 (5) :477-490.|Cell Signal. 2025 Apr 15:132:111807.|Curr Eye Res. 2024 Aug;49 (8) :862-871.|Eur J Pharmacol. 2022 Oct 15:933:175271.|FASEB J. 2024 Jan 31;38 (2) :e23417.|Haematologica. 2020 Mar;105 (3) :674-686.|Int Immunopharmacol. 2021 Jul:96:107511.|Int Immunopharmacol. 2024 Oct 31;143 (Pt 3) :113526.|Int Immunopharmacol. 2025 Mar 22:153:114495.|J Immunol Sci. March 31, 2022.|J Immunol. 2024 Nov 15;213 (10) :1499-1507.|J Immunother Cancer. 2025 Feb 6;13 (2) :e010150.|J Immunother Cancer. 2025 Jul 15;13 (7) :e010926.|J Inflamm Res. 2025 Feb 14:18:2229-2245.|J Med Chem. 2025 May 8;68 (9) :9723-9740.|Life Sci. 2019 Jan 15:217:243-250.|Nat Cardiovasc Res. 2025 Feb;4 (2) :216-234.|Nat Commun. 2022 Jan 10;13 (1) :182.|Nat Commun. 2024 Jun 13;15 (1) :5056.|Nat Commun. 2024 May 31;15 (1) :4665.|Nat Commun. 2024 Sep 8;15 (1) :7850.|Nat Genet. 2025 Dec;57 (12) :3050-3065.|Nature. 2025 Nov;647 (8090) :706-715.|Patent. US20210393524A1.|Phytomedicine. 2025 May 27:143:156919.|Phytomedicine. 2025 May 30:144:156917.|Phytomedicine. 2025 Sep 19:148:157271.|PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |Reprod Biomed Online. 2023 Nov;47 (5) :103304.|Research Square Preprint. 2023 Dec 1.|Signal Transduct Target Ther. 2025 Mar 24;10 (1) :101.|Theranostics. 2021 Jan 1;11 (1) :117-131.|Vet Microbiol. 2021 Oct:261:109177.

• CAS Number :

  [162359-55-9]